Aspire Biopharma Holdings (ASBP) Interest Expenses (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has 3 years of Interest Expenses data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 450.24% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 2815.53% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, up 856.82% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.6 million, down from $6.2 million in the prior quarter.
• Over the last five years, Interest Expenses for ASBP reached as high as $6.2 million in Q4 2025 and fell as low as -$72083.0 in Q4 2024.
• Historically, Interest Expenses has averaged $1.3 million across 3 years, with a median of $408912.0 in 2025.
• On a YoY basis, Interest Expenses climbed as much as 8747.52% in 2025 and fell as far as 58.16% in 2025.
• Year by year, Interest Expenses stood at -$72083.0 in 2024, then soared by 8747.52% to $6.2 million in 2025, then tumbled by 74.41% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $1.6 million in Q1 2026, $6.2 million in Q4 2025, and $1.5 million in Q3 2025.